[Edaily Reporter NA EUN-KYUNG ] DuChemBio Co.,LTD.(176750)Market interest is growing as the company anticipates increased demand for dementia diagnostic tests following the expansion of treatment options for Alzheimer’s disease. Recent stock price gains, coupled with rising trading volume, are highlighting expectations for further growth. This is because, following a significant increase in sales of amyloid diagnostic tests since the launch of Lecembi, the introduction of Eli Lilly’s “Kysena” to the domestic market could further boost demand for diagnostic testing during treatment.
According to the Korea Exchange on the 13th, DuChemBio Co, LTD closed at 7,570 won on the 8th, marking a 26.0% increase over 10 trading days compared to the 21st of last month. On the 29th of last month, the stock rose 12.25%, with approximately 454,000 shares traded—the highest trading volume since July 27. The upward trend continued on the 2nd and 7th of this month, with approximately 146,000 and 179,000 shares traded, respectively.
Comparison of PET-CT images using “Bizamil” (top color photo) and “NeuraCheck” (bottom black-and-white photo), both used for diagnosing Alzheimer’s dementia (Source: DuChemBio Co, LTD)
Diagnostic Sales Growth Accelerates Following Lecembi’s Launch
DuChemBio Co, LTD is the exclusive domestic manufacturer and supplier of “Bizamil” and “NeuraCheck,” which are used in amyloid positron emission tomography (PET) scans. Amyloid PET scans are used to detect amyloid accumulation in the brain and to identify candidates for anti-amyloid therapy.
Kim Seung-woo, Executive Vice President and Head of the Growth Strategy Division at DuChemBio Co, LTD, stated, “Sales of the two products, Vizamil and Neuracheck, increased from 5.1 billion won in 2024 to 7.5 billion won last year.” He added, “Last year, when prescriptions for Lecembi began in earnest, we saw sales growth of approximately 46–47 percent. The launch of Lecembi clearly had a positive impact.”
Lekembi received approval from the Ministry of Food and Drug Safety (MFDS) in May 2024 and was launched in South Korea in November of the same year. In the first half of this year—the third year since its launch—sales of Vizamil and Neuracheck totaled 4.55 billion won, already reaching 61% of last year’s sales in just six months. This represents a 38.2% increase compared to the same period last year.
The domestic market has also expanded. According to data analyzed by DuChemBio Co, LTD based on product-specific production figures from the Ministry of Food and Drug Safety’s “Drug Safety Korea” portal, the production value of radiopharmaceuticals for diagnosing Alzheimer’s dementia rose by approximately 53%, from 8.03 billion won in 2024 to 12.27 billion won last year. Last year, the production value of DuChemBio Co, LTD’s two products totaled 11.81 billion won, representing a 96.3% market share based on production value.
Will Kisunra Expand Demand to Include In-Treatment Testing?
Kisunra is cited as a factor for further growth. Eli Lilly Korea applied for domestic marketing authorization last December, and industry observers predict approval could come as early as this month. If the approval process proceeds smoothly, a domestic launch is expected early next year.
Kysunra’s U.S. prescribing information specifies that discontinuation of treatment may be considered once amyloid plaques have decreased to minimal levels on an amyloid PET scan. This structure requires determining whether to discontinue treatment based on in-treatment testing, in addition to patient screening prior to treatment initiation. While the domestic testing schedule and application methods will depend on future approval conditions and clinical guidelines, if approved under the same conditions as in the U.S., there could be demand for additional testing to confirm whether treatment should be discontinued.
A biotech industry official explained, “While doctors sometimes recommend mid-treatment testing for Lecembi, it is not mandatory,” adding, “In contrast, since Kysunra allows for mid-treatment testing to confirm whether amyloid has been reduced to a certain level before discontinuing treatment, we anticipate an increase in demand for diagnostic tests.”
The pace of growth ultimately depends on the expansion of Kisunra prescriptions. With Lecembi already in use, Lilly Korea must convince healthcare providers; the speed at which Kisunra replaces existing products and the extent to which it taps into new markets will determine how quickly sales of diagnostic kits will grow.
Improving Access to Testing and Increasing Investment in Production Facilities
Although bottlenecks—resulting in delays in treatment and testing—are occurring as patients flock to large hospitals, the company explains that waiting times for tests and patient congestion are gradually easing, leaving room for even steeper growth in diagnostic test sales next year.
An industry insider stated, “At its worst, it reportedly took three months just to get an initial consultation, followed by another three months for a PET scan,” adding, “Although waiting times have now been cut roughly in half, bottlenecks still exist at major hospitals in Seoul.” The company views this as the primary reason why its revenue growth rate in the first half of this year fell short of initial expectations.
To address this, DuChemBio Co, LTD is pursuing measures to improve access to testing by expanding its network of partner hospitals. Executive Director Kim stated, “If patients undergo testing at other hospitals, they can receive treatment more quickly without encountering bottlenecks,” adding, “It takes time because medical staff must be prepared so that patients can trust and visit these facilities, but we are continuing our efforts.”
Investments in manufacturing facilities to prepare for increased demand are also underway. Executive Vice President Kim explained, “The investment in the Hanyang University Hospital manufacturing facility is intended to meet the growing domestic demand for radiopharmaceutical diagnostic products, including amyloid PET diagnostic agents.” In the medium to long term, the company plans to secure supply capacity by investing in production facilities within the High-Tech Industrial Zone in Sinjeong-dong, Jeongeup, North Jeolla Province.
The company maintains that, until the Jeongeup plant is completed, it can meet additional demand by increasing the number of production runs at existing facilities. Executive Director Kim emphasized, “Generally, we run three production cycles during an 8-hour workday, but at manufacturing centers with high demand, we are running up to five cycles,” adding, “By increasing the number of production runs, we can meet additional demand in line with the delivery times requested by hospitals.”
#Xcell Therapeutics Inc. is pursuing a third-party private placement worth 7 to 8 billion won to avoid the risk of negative equity by year-end. This comes after the company raised funds through a 9.5 …
Kim Dong-seon, President of Future Strategy at #Hanwha Machinery & Service Holdings (Hanwha M&S), is launching an additional tender offer for Hanwha M&S shares, investing approximately 27 billion won.…
NIBEC CO., LTD.(138610)is seeking to expand its collaboration with global pharmaceutical companies. The company plans to discuss partnerships focused on obesity treatments that simultaneously target b…